ECE2015 Eposter Presentations Calcium and Vitamin D metabolism (96 abstracts)
Patients with new onset diabetes after liver transplantation have higher sclerostin levels that tend to decrease after an oral glucose tolerance test
Guillermo Martínez Díaz-Guerra 1 , Gonzalo Allo Miguel 1 , Mercedes Aramendi Ramos 2 , Soledad Librizzi 1 , Sonsoles Guadalix Iglesias 1 , Elena García Fernández 1 & Federico Hawkins Carranza 1
1Endocrinology Service, 12 de Octubre University Hospital, Madrid, Spain; 2Laboratory Service, 12 de Octubre University Hospital, Madrid, Spain.
Introduction: Decreased bone formation has been proposed as a mechanism involved in the higher risk of fractures in diabetic patients. Some clinical studies have found that sclerostin (SCL, a negative regulator of bone formation) is increased in diabetic patients. However, there is no information about the relationship between SCL and new onset diabetes after transplantation (NODAT). The aim of our study is to evaluate serum SCL levels in a cohort of patients with liver transplantation (LT).
Patients and methods: 85 LT patients without previous diabetes mellitus were enrolled. A 75 g oral glucose tolerance test was performed (OGTT) and diagnostic ADA criteria were followed. Serum SCL was measured in fasting, 60- and 120-min samples during OGTT. MANOVA test were used to evaluate the evolution of sclerostin levels (from baseline to 120-min).
Results: 48 patients (64%) showed normal glucose tolerance (NGT), 31 (36.4%) impaired glucose tolerance (IGT) and six NODAT (7.05%). Results of SCL for OTTG were (ng/ml; baseline, 60′, 120′): i) NGT: 0.70±0.27/0.65±0.22/0.69±0.23 ng/ml; ii) IGT: 0.83±0.31/0.71±0.20/0.75±0.20 ng/ml; iii) NODAT: 1.75±1.20/1.55±1.24/1.46±1.1 ng/ml. SCL levels were significantly higher in NODAT patients at baseline (P<0.001); 60′ (P<0.001) and 120′ (P=0.001). During OGTT, sclerostin showed a significant decrease (P=0.01), which was more pronounced in the NODAT group, with a percent of change of: −0.32±0.64.
Conclusions: Our results show that after LT basal SCL levels are higher in patients with NODAT than in patients with prediabetes or NGT. Also, we have found that during an OGTT sclerostin significantly decrease, particularly in NODAT patients. Based on our results, we suggest further studies to investigate a plausible link between higher levels of sclerostin in NODAT patients and their increased fracture risk.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more